NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 21 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Follow-Up Questions
Quelle est la performance du prix de l'action NRXS ?
Le prix actuel de NRXS est de $2.53, il a decreased de 2.91% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Neuraxis Inc ?
Neuraxis Inc appartient à l'industrie Health Care et le secteur est Health Care
Quelle est la capitalisation boursière de Neuraxis Inc ?
La capitalisation boursière actuelle de Neuraxis Inc est de $25.0M
Est-ce que Neuraxis Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Neuraxis Inc, y compris 2 achat fort, 5 achat, 1 maintien, 0 vente et 2 vente forte
